Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Peginterferon α‐2b plus ribavirin compared with interferon α‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4

Peginterferon α‐2b plus ribavirin compared with interferon α‐2b plus ribavirin for initial... Abstract: Aim: Comparing the efficacy of peginterferon α‐2b plus ribavirin with interferon α ‐2b plus ribavirin in Saudi patients with chronic hepatitis C virus (HCV) commonly infected with genotype 4. Methods: A total of 96 patients with chronic HCV infection were randomly assigned to two treatment groups. Forty‐eight patients received once weekly 100 μg of peginterferon α‐2b plus ribavirin given orally 800 mg/day (peginterferon group). Another 48 patients received thrice weekly 3 million units of interferon α‐2b plus ribavirin 800 mg/day (interferon group). At the end of treatment (48 weeks) and sustained (72 weeks) biochemical and virologic responses were determined. Results: In the peginterferon group, 70.8% (34/48) patients attained both biochemical and virologic responses at the end of the treatment as against 52.1% (25/48) patients in the interferon group. (P=0.09 for both). Similarly, sustained biochemical and virologic responses in the peginterferon group were attained in 52.1% (25/48) and 43.8% (21/48) patients as against 43.8% (21/48) and 29.2% (14/48) patients in the interferon group, respectively (P=0.54 and 0.20, respectively). The sustained virologic response rates in patients with genotype 4 were 42.9% (12/28) in the peginterferon group and 32.3% (10/31) in the interferon group (P=0.43). Patients in peginterferon group had higher, although statistically not significant adverse reactions. Conclusions: Saudi patients with chronic HCV attained a higher, although statistically not significant sustained virologic response with pegylated interferon plus ribavirin compared with interferon plus ribavirin. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Liver International Wiley

Peginterferon α‐2b plus ribavirin compared with interferon α‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4

Download PDF
7 pages

Loading next page...
 
/lp/wiley/peginterferon-2b-plus-ribavirin-compared-with-interferon-2b-plus-sE7Ii0mQDd

References (42)

Publisher
Wiley
Copyright
Copyright © 2004 Wiley Subscription Services, Inc., A Wiley Company
ISSN
1478-3223
eISSN
1478-3231
DOI
10.1111/j.1478-3231.2004.0976.x
pmid
15566506
Publisher site
See Article on Publisher Site

Abstract

Abstract: Aim: Comparing the efficacy of peginterferon α‐2b plus ribavirin with interferon α ‐2b plus ribavirin in Saudi patients with chronic hepatitis C virus (HCV) commonly infected with genotype 4. Methods: A total of 96 patients with chronic HCV infection were randomly assigned to two treatment groups. Forty‐eight patients received once weekly 100 μg of peginterferon α‐2b plus ribavirin given orally 800 mg/day (peginterferon group). Another 48 patients received thrice weekly 3 million units of interferon α‐2b plus ribavirin 800 mg/day (interferon group). At the end of treatment (48 weeks) and sustained (72 weeks) biochemical and virologic responses were determined. Results: In the peginterferon group, 70.8% (34/48) patients attained both biochemical and virologic responses at the end of the treatment as against 52.1% (25/48) patients in the interferon group. (P=0.09 for both). Similarly, sustained biochemical and virologic responses in the peginterferon group were attained in 52.1% (25/48) and 43.8% (21/48) patients as against 43.8% (21/48) and 29.2% (14/48) patients in the interferon group, respectively (P=0.54 and 0.20, respectively). The sustained virologic response rates in patients with genotype 4 were 42.9% (12/28) in the peginterferon group and 32.3% (10/31) in the interferon group (P=0.43). Patients in peginterferon group had higher, although statistically not significant adverse reactions. Conclusions: Saudi patients with chronic HCV attained a higher, although statistically not significant sustained virologic response with pegylated interferon plus ribavirin compared with interferon plus ribavirin.

Journal

Liver International – Wiley

Published: Dec 1, 2004

There are no references for this article.